---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-111310"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:08:27.730475+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oramed reports nine-month 2025 net income of $65M, up from loss of $6.1M

## Summary
- Net income (pre-tax) of $65.0M vs. $6.1M loss; basic EPS $1.30, diluted $1.26.
- Full $100M repayment from Scilex completed; $27M received in the period.
- Total assets up 42% to $220.5M; driven by cash returns and unrealized gains on Alpha Tau (DRTS).
- R&D expenses fell to $4.4M from $4.9M; G&A rose to $5.0M from $4.3M.
- Unrealized fair-value gains on equity holdings in Alpha Tau and other investments contributed to income.

## SEC filing metadata
- accession: 0001213900-25-111310
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025111310/0001213900-25-111310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025111310/ea0265949-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-111310
- JSON: https://secwatch.observer/filing/0001213900-25-111310.json
- Plain text: https://secwatch.observer/filing/0001213900-25-111310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.